Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RVI smoking $2.27 owns $6 / share worth of DSW
http://seekingalpha.com/article/126298-retail-ventures-hidden-value?source=yahoo
RVI smoking $2.27 owns $6 / share worth of DSW
http://seekingalpha.com/article/126298-retail-ventures-hidden-value?source=yahoo
TRM $100 MM contract
http://finance.yahoo.com/news/Trico-Marine-Group-Awarded-pz-15042286.html
Huge news.
$4.12 was $41 last year
CKSW at $3.33 a Growth Gem. Find me another sub $5 stock in this environment with $.17 EPS last quarter 31% growth and $7 Million cash flow to boot. They said first month of 2009 was strong too. This has Motley fool coveted 5 star rating and I can see why.
http://finance.yahoo.com/news/ClickSoftware-Reports-31-prnews-14246058.html
CNTF exploding $1.55 $2 / share cash profitable no debt 3G play moving on SCON sympathy
http://finance.yahoo.com/news/TechFaith-Reports-Fourth-iw-14585940.html
CNTF most undervalued NAS stock IMO
$2 / share cash
$3 / share cash + inventory
no debt
Profitable and growing.
3 G rollout beneficiary.
CNTF exploding $1.55 $2 / share cash profitable no debt 3G play moving on SCON sympathy
http://finance.yahoo.com/news/TechFaith-Reports-Fourth-iw-14585940.html
CNTF most undervalued NAS stock IMO
$2 / share cash
$3 / share cash + inventory
no debt
Profitable and growing.
3 G rollout beneficiary.
Next Bio blockbuster? A possible DNDN:
MAPP:NASDAQ $3.15
Small float
$4 / share cash after $40 MM milestone payment in January
Was $11 a few months ago
Migraine Drug HUGE
http://www.reuters.com/article/marketsNe...
DVAX $.91 ran to $2.50 in december Bio run trading at half cash value
http://finance.yahoo.com/q/bs?s=DVAX&annual
DVAX $.91 ran to $2.50 in december Bio run trading at half cash value
http://finance.yahoo.com/q/bs?s=DVAX&annual
DVAX $.91 ran to $2.50 in december Bio run trading at half cash value
http://finance.yahoo.com/q/bs?s=DVAX&annual
ASYT NASDAQ penny laggard moving
-There are still outstanding penny stocks laggards left.. ASYT is the cheapest quality laggard.
-$83 MM sales last quarter
-EBITDA positive
Reduced breakeven to $55 MM sales commecing April 1
-Backlog is INCREASING
Steve Schwartz, chair and chief executive officer of Asyst, said, "We have taken significant action over the past several months to reduce the company’s cash breakeven level and to position the business for the challenging economic environment. Over the first three quarters of the current fiscal year, we have reduced ongoing annual operating expenses by approximately $25 million and reduced the quarterly cash breakeven sales level to approximately $75 million. In the fiscal fourth quarter we are taking further actions, which we expect will result in an additional $30-$35 million of annual savings and a $55 million quarterly cash breakeven level entering the fiscal year that begins April 1. In the fiscal third quarter we achieved gross margin of 31%, up significantly from the prior sequential quarter despite lower volume. This is consistent with our objectives
ASYT NASDAQ penny laggard moving
-There are still outstanding penny stocks laggards left.. ASYT is the cheapest quality laggard.
-$83 MM sales last quarter
-EBITDA positive
Reduced breakeven to $55 MM sales commecing April 1
-Backlog is INCREASING
Steve Schwartz, chair and chief executive officer of Asyst, said, "We have taken significant action over the past several months to reduce the company’s cash breakeven level and to position the business for the challenging economic environment. Over the first three quarters of the current fiscal year, we have reduced ongoing annual operating expenses by approximately $25 million and reduced the quarterly cash breakeven sales level to approximately $75 million. In the fiscal fourth quarter we are taking further actions, which we expect will result in an additional $30-$35 million of annual savings and a $55 million quarterly cash breakeven level entering the fiscal year that begins April 1. In the fiscal third quarter we achieved gross margin of 31%, up significantly from the prior sequential quarter despite lower volume. This is consistent with our objectives
Chreapest NASDAQ penny laggard:
ASYT $.53 + $.07 $450 MM annual sales EBITDA POSITIVE
-There are still outstanding penny stocks laggards left.. ASYT is the cheapest quality laggard.
-$83 MM sales last quarter
-EBITDA positive
Reduced breakeven to $55 MM sales commecing April 1
-Backlog is INCREASING
Steve Schwartz, chair and chief executive officer of Asyst, said, "We have taken significant action over the past several months to reduce the company’s cash breakeven level and to position the business for the challenging economic environment. Over the first three quarters of the current fiscal year, we have reduced ongoing annual operating expenses by approximately $25 million and reduced the quarterly cash breakeven sales level to approximately $75 million. In the fiscal fourth quarter we are taking further actions, which we expect will result in an additional $30-$35 million of annual savings and a $55 million quarterly cash breakeven level entering the fiscal year that begins April 1. In the fiscal third quarter we achieved gross margin of 31%, up significantly from the prior sequential quarter despite lower volume. This is consistent with our objectives
ASYT $.33 +$.06 $450 MM annual sales EBITDA positive
ASYT next NASDAQ pennt tripler
This is a QUALITY EBITDA positive company
Reduced breakeven to $55 MM sales had $80 MM sales in last quarter:
Steve Schwartz, chair and chief executive officer of Asyst, said, "We have taken significant action over the past several months to reduce the company’s cash breakeven level and to position the business for the challenging economic environment. Over the first three quarters of the current fiscal year, we have reduced ongoing annual operating expenses by approximately $25 million and reduced the quarterly cash breakeven sales level to approximately $75 million. In the fiscal fourth quarter we are taking further actions, which we expect will result in an additional $30-$35 million of annual savings and a $55 million quarterly cash breakeven level entering the fiscal year that begins April 1. In the fiscal third quarter we achieved gross margin of 31%, up significantly from the prior sequential quarter despite lower volume. This is consistent with our objectives and reflects continuing improvements in our supply chain. Bookings in the fiscal third quarter were $92 million, which allowed us to build backlog for the second consecutive quarter. All of these accomplishments are positioning us to weather what we believe will continue to be a challenging environment in the coming fiscal year.”
ASYT $.33 +$.06 $450 MM annual sales EBITDA positive
ASYT next NASDAQ pennt tripler
This is a QUALITY EBITDA positive company
Reduced breakeven to $55 MM sales had $80 MM sales in last quarter:
Steve Schwartz, chair and chief executive officer of Asyst, said, "We have taken significant action over the past several months to reduce the company’s cash breakeven level and to position the business for the challenging economic environment. Over the first three quarters of the current fiscal year, we have reduced ongoing annual operating expenses by approximately $25 million and reduced the quarterly cash breakeven sales level to approximately $75 million. In the fiscal fourth quarter we are taking further actions, which we expect will result in an additional $30-$35 million of annual savings and a $55 million quarterly cash breakeven level entering the fiscal year that begins April 1. In the fiscal third quarter we achieved gross margin of 31%, up significantly from the prior sequential quarter despite lower volume. This is consistent with our objectives and reflects continuing improvements in our supply chain. Bookings in the fiscal third quarter were $92 million, which allowed us to build backlog for the second consecutive quarter. All of these accomplishments are positioning us to weather what we believe will continue to be a challenging environment in the coming fiscal year.”
ASYT $.33 +$.06 $450 MM annual sales EBITDA positive
ASYT next NASDAQ pennt tripler
This is a QUALITY EBITDA positive company
Reduced breakeven to $55 MM sales had $80 MM sales in last quarter:
Steve Schwartz, chair and chief executive officer of Asyst, said, "We have taken significant action over the past several months to reduce the company’s cash breakeven level and to position the business for the challenging economic environment. Over the first three quarters of the current fiscal year, we have reduced ongoing annual operating expenses by approximately $25 million and reduced the quarterly cash breakeven sales level to approximately $75 million. In the fiscal fourth quarter we are taking further actions, which we expect will result in an additional $30-$35 million of annual savings and a $55 million quarterly cash breakeven level entering the fiscal year that begins April 1. In the fiscal third quarter we achieved gross margin of 31%, up significantly from the prior sequential quarter despite lower volume. This is consistent with our objectives and reflects continuing improvements in our supply chain. Bookings in the fiscal third quarter were $92 million, which allowed us to build backlog for the second consecutive quarter. All of these accomplishments are positioning us to weather what we believe will continue to be a challenging environment in the coming fiscal year.”
CNO CEO Buys 200,000 Shares
CEO PRIEUR buys 200,000 shares CNO
dow jones - SEC filing just hit
CNO CEO Buys 200,000 Shares
CEO PRIEUR buys 200,000 shares CNO
dow jones - SEC filing just hit
LVLT $5 this year imo
CNO $.85 + $.17 Credit AMENDMENT 1 X EBITDA
With new Credit amendment no more liquidity concerns. CNO will go back to $15 fair value (12 X EBITDA)
http://finance.yahoo.com/news/Conseco-Cl...
CNO $.85 + $.17 Credit AMENDMENT 1 X EBITDA
With new Credit amendment no more liquidity concerns. CNO will go back to $15 fair value (12 X EBITDA)
http://finance.yahoo.com/news/Conseco-Cl...
ACLS:NASDAQ $120 MM sale $2.5 share liquid asstes for $.42
After the $120 MM sale today ACLS has $250 MM cash + inventory:
September 30 2008 liquid assets:
http://finance.yahoo.com/q/bs?s=ACLS
$295 MM - $135 MM = $160 MM
Assume conservatively $15 MM cash burn per Q
March 30 2008 liquid assets =
$160 MM - #30 MM cash burn + $120 MM sale proceeds
= $250 MM or $2.50 per share
HUGE News ACLS:NASDAQ $120 MM sale $.42 was $6 in 2008
http://finance.yahoo.com/news/Axcelis-Technologies-pz-14783042.html
This solves ACLS liquidity isssues that caused it to drop from $6
HUGE News ACLS:NASDAQ $120 MM sale $.42 was $6 in 2008
http://finance.yahoo.com/news/Axcelis-Technologies-pz-14783042.html
This solves ACLS liquidity isssues that caused it to drop from $6
LVLT Great call. $2 soon see todays filing
LVLT:NASDAQ profitable $.85 + $.06 gonna be a MONSTER
PROFOITABLE telecom in last quarter huge volume big contract just signed with telefonica
http://finance.yahoo.com/q/is?s=LVLT
LVLT:NASDAQ profitable $.85 + $.06 gonna be a MONSTER
PROFOITABLE telecom in last quarter huge volume big contract just signed with telefonica
http://finance.yahoo.com/q/is?s=LVLT
That was me this stock is a GEM. $2 tomorrow
GBE:NYSE $.57 +$.16 Huge play in commercial real estate FACILITATES REAL ESTATE TRANSACTIONS AND REFINANCING. Was $8 last year, Positive $30 MM EBITDA before charges.
GBE:NYSE $.57 +$.16 Huge play in commercial real estate FACILITATES REAL ESTATE TRANSACTIONS AND REFINANCING. Was $8 last year, Positive $30 MM EBITDA before charges.
ALY $1.40 + $.40 Oil and Gas MOMO Just starting run to $3 next SGY anfd PQ which went from pennies to $3 + in a days huge insider buying.
http://finance.yahoo.com/q/it?s=ALY
ALY $1.40 + $.40 Oil and Gas MOMO Just starting run to $3 next SGY anfd PQ which went from pennies to $3 + in a days huge insider buying.
http://finance.yahoo.com/q/it?s=ALY
GRO $.86 $3 / share cash No debt hot China AG sector
http://finance.yahoo.com/q/bs?s=GRO&annual
GRO $.86 $3 / share cash No debt hot China AG sector
http://finance.yahoo.com/q/bs?s=GRO&annual
bought 25000 sfi at $2. Loving it ! Also nailed FEED.
2 Core PE Ratio: FCSX:NASDAQ MOVING $1.80
FCSX is in a recssion proof business, commodity trading clearing house. Their stock declined due to one bad debt account which they sold this week. Was $55 a few years ago.
- Core operating earnings before charges of $2 / share. Now that one time charges are behind them markets will look forward at FCSX huge earnings power and bid up the forward PE. Even with a 3 foreard PE FCSX is a $6 stock.
-Takeover Target: Barclays recently made a sizeable investment in FCSX. Barclays is focused on increasing US presence- they bought Lehman broker operations.
- This sector has been one of the hottest areas, MF has more than doubled.
-Undervalued compared to peers: FCSX has a much smaller float and market cap than MF or GFIG
2 Core PE Ratio: FCSX:NASDAQ MOVING $1.80
FCSX is in a recssion proof business, commodity trading clearing house. Their stock declined due to one bad debt account which they sold this week. Was $55 a few years ago.
- Core operating earnings before charges of $2 / share. Now that one time charges are behind them markets will look forward at FCSX huge earnings power and bid up the forward PE. Even with a 3 foreard PE FCSX is a $6 stock.
-Takeover Target: Barclays recently made a sizeable investment in FCSX. Barclays is focused on increasing US presence- they bought Lehman broker operations.
- This sector has been one of the hottest areas, MF has more than doubled.
-Undervalued compared to peers: FCSX has a much smaller float and market cap than MF or GFIG
FCSX busting out going to $4 soon:
- Core operating earnings before charges of $2 / share. Now that one time charges are behind them markets will look forward at FCSX huge earnings power and bid up the forward PE. Even with a 3 foreard PE FCSX is a $6 stock.
-Takeover Target: Barclays recently made a sizeable investment in FCSX. Barclays is focused on increasing US presence- they bought Lehman broker operations.
- This sector has been one of the hottest areas, MF has more than doubled.
-Undervalued compared to peers: FCSX has a much smaller float and market cap than MF or GFIG.
ACAS:NASDSAQ $.98 $7 in January Massive insider buys $15 book value huge benefit from mark to market rules
RUS:NYSE $1.38 $.64 pro forma EPS
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001104659%2D09%2D016635%2Etxt&FilePath=%5C2009%5C03%5C12%5C&CoName=RUSS+BERRIE+%26+CO+INC&FormType=8%2DK%2FA&RcvdDate=3%2F12%2F2009&pdf=
after sale of gift business